Tarsus Pharmaceuticals TARS Stock
Tarsus Pharmaceuticals Price Chart
Tarsus Pharmaceuticals TARS Financial and Trading Overview
| Tarsus Pharmaceuticals stock price | 36.17 USD |
| Previous Close | 18.59 USD |
| Open | 18.58 USD |
| Bid | 0 USD x 1100 |
| Ask | 0 USD x 900 |
| Day's Range | 18.15 - 18.74 USD |
| 52 Week Range | 11.33 - 20.09 USD |
| Volume | 289.44K USD |
| Avg. Volume | 177.08K USD |
| Market Cap | 499.08M USD |
| Beta (5Y Monthly) | 0.62967 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.62 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 47.38 USD |
TARS Valuation Measures
| Enterprise Value | 322.28M USD |
| Trailing P/E | N/A |
| Forward P/E | -5.4604106 |
| PEG Ratio (5 yr expected) | 0.19 |
| Price/Sales (ttm) | 17.96756 |
| Price/Book (mrq) | 2.8778982 |
| Enterprise Value/Revenue | 11.602 |
| Enterprise Value/EBITDA | -4.757 |
Trading Information
Tarsus Pharmaceuticals Stock Price History
| Beta (5Y Monthly) | 0.62967 |
| 52-Week Change | 43.56% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 20.09 USD |
| 52 Week Low | 11.33 USD |
| 50-Day Moving Average | 15.61 USD |
| 200-Day Moving Average | 15.62 USD |
TARS Share Statistics
| Avg. Volume (3 month) | 177.08K USD |
| Avg. Daily Volume (10-Days) | 250.17K USD |
| Shares Outstanding | 26.8M |
| Float | 13.96M |
| Short Ratio | 5.8 |
| % Held by Insiders | 13.12% |
| % Held by Institutions | 77.58% |
| Shares Short | 909.76K |
| Short % of Float | 3.61% |
| Short % of Shares Outstanding | 3.39% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -234.98% |
| Operating Margin (ttm) | -245.32% |
| Gross Margin | -57.75% |
| EBITDA Margin | -243.92% |
Management Effectiveness
| Return on Assets (ttm) | -21.69% |
| Return on Equity (ttm) | -40.46% |
Income Statement
| Revenue (ttm) | 27.78M USD |
| Revenue Per Share (ttm) | 1.06 USD |
| Quarterly Revenue Growth (yoy) | 363.80% |
| Gross Profit (ttm) | -17763000 USD |
| EBITDA | -67755000 USD |
| Net Income Avi to Common (ttm) | -65272000 USD |
| Diluted EPS (ttm) | -2.46 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 201.22M USD |
| Total Cash Per Share (mrq) | 7.51 USD |
| Total Debt (mrq) | 25.22M USD |
| Total Debt/Equity (mrq) | 14.54 USD |
| Current Ratio (mrq) | 15.741 |
| Book Value Per Share (mrq) | 6.47 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -55714000 USD |
| Levered Free Cash Flow (ttm) | -32859750 USD |
Profile of Tarsus Pharmaceuticals
| Country | United States |
| State | CA |
| City | Irvine |
| Address | 15440 Laguna Canyon Road |
| ZIP | 92618 |
| Phone | 949 409 9820 |
| Website | https://www.tarsusrx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 87 |
Tarsus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
Q&A For Tarsus Pharmaceuticals Stock
What is a current TARS stock price?
Tarsus Pharmaceuticals TARS stock price today per share is 36.17 USD.
How to purchase Tarsus Pharmaceuticals stock?
You can buy TARS shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Tarsus Pharmaceuticals?
The stock symbol or ticker of Tarsus Pharmaceuticals is TARS.
Which industry does the Tarsus Pharmaceuticals company belong to?
The Tarsus Pharmaceuticals industry is Biotechnology.
How many shares does Tarsus Pharmaceuticals have in circulation?
The max supply of Tarsus Pharmaceuticals shares is 37.5M.
What is Tarsus Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
Tarsus Pharmaceuticals PE Ratio is now.
What was Tarsus Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
Tarsus Pharmaceuticals EPS is -4.62 USD over the trailing 12 months.
Which sector does the Tarsus Pharmaceuticals company belong to?
The Tarsus Pharmaceuticals sector is Healthcare.
Tarsus Pharmaceuticals TARS included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ Global Select Market Com NQGS | 7876.03 USD — |
-1.61
|
— — | 7852.08 USD — | 7955.84 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4195.13 USD — |
-2.14
|
— — | 4174.1 USD — | 4266.29 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
| Stlmt ID NASDAQ Biotechnology NBX | 4604.4 USD — |
-2.98
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
- {{ link.label }} {{link}}